Pancreatic enzyme pharmacotherapy

Pharmacotherapy

Volumn 27, Issue 6, 2007, Pages 910-920

  Ferrone, Marcus ^a   Raimondo, Massimo ^b   Scolapio, James S ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b MAYO CLINIC   (United States)

Author keywords

Cystic fibrosis; Pancreatic enzymes; Pancreatitis; Pancrelipase

Indexed keywords

BICARBONATE; BICARBONATE PLUS PANCRELIPASE; CIMETIDINE; CREON 10 SR; CREON 20 SR; CREON 5 SR; KU ZYME HP; LIPRAM 4500 DR; LIPRAM CR10 DR; LIPRAM CR20 DR; LIPRAM PN10 DR; LIPRAM PN16 DR; LIPRAM PN20 DR; LIPRAM UL12 DR; LIPRAM UL18 DR; LIPRAM UL20 DR; PALCAPS 10 DR; PALCAPS 20 DR; PANCREAS ENZYME; PANCREASE MT 16; PANCREASE MT 20; PANCREASE MT10; PANCREASE MT4; PANCRECARB; PANCRECARB MS 16 DR; PANCRECARB MS 4 DR; PANCRECARB MS 8 DR; PANCRELIPASE; PANGESTYME CN 10 DR; PANGESTYME CN 20 DR; PANGESTYME EC; PANGESTYME UL12 DR; PANGESTYME UL18 DR; PANGESTYME UL20 DR; PANOCAPS MT 16 DR; PANOCAPS MT 20 DR; PLARETASE; TRIACYLGLYCEROL LIPASE; ULTRASE MT 18; ULTRASE MT 20; ULTRASE MT12; UNCLASSIFIED DRUG; VIOKASE 16; VIOKASE 8;

ANALGESIA; CHRONIC PANCREATITIS; CLINICAL PRACTICE; CYSTIC FIBROSIS; DIFFERENTIAL DIAGNOSIS; DRUG FORMULATION; ENTERIC COATED TABLET; ENZYME REPLACEMENT; HUMAN; LIPID ABSORPTION; REVIEW; STEATORRHEA; TREATMENT FAILURE;

CYSTIC FIBROSIS; DIGESTION; EXOCRINE PANCREATIC INSUFFICIENCY; GASTROINTESTINAL AGENTS; HUMANS; PAIN; PANCREAS; PANCREATIN; PANCREATITIS; PANCRELIPASE;

EID: 34249784817     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.27.6.910     Document Type: Review

References (69)

1. Pezzilli R, Morselli Labate AM, Ceciliato R, et al. Quality of life in patients with chronic pancreatitis. Dig Liver Dis 2005;37:181-9.
2. 2, and fatty acid for the digestion of dietary fat: in vitro experiments with the porcine enzymes. Gastroenterology 1980;78:954-62.
3. Hamosh M. Lingual lipase. Gastroenterology 1986;90:1290-2.
4. Dutta SK, Russell RM, Iber FL. Impaired acid neutralization in the duodenum in pancreatic insufficiency. Dig Dis Sci 1979;24:775-80.
5. Go VL, Poley JR, Hofmann AF, Summerskill WH. Disturbances in fat digestion induced by acidic jejunal pH due to gastric hypersecretion in man. Gastroenterology 1970;58: 638-46.
6. 2 activity of human small intestinal contents. Acta Chem Scand 1973;27:2749-56.
7. Hofmann AF. Lipase, colipase, amphipathic dietary proteins, and bile acids: new interactions at an old interface. Gastroenterology 1978;75:530-2.
8. DiMagno EP, Go VL, Summerskill WH. Relations between pancreatic enzyme ouputs and malabsorption in severe pancreatic insufficiency. N Engl J Med 1973;288:813-15.
9. 2 breath test. Gastroenterology 1989;96:503-9.
10. Layer P, Zinsmeister AR, DiMagno EP. Effects of decreasing intraluminal amylase activity on starch digestion and postprandial gastrointestinal function in humans. Gastroenterology 1986;91:41-8.
11. Keller J, Runzi M, Goebell H, Layer P. Duodenal and ileal nutrient deliveries regulate human intestinal motor and pancreatic responses to a meal. Am J Physiol 1997;272:G632-7.
12. Layer P, Schlesinger T, Groger G, Goebell H. Modulation of human periodic interdigestive gastrointestinal motor and pancreatic function by the ileum. Pancreas 1993;8:426-32.
13. Borgstrom B, Dahlqvist A, Lundh G, Sjovall J. Studies of intestinal digestion and absorption in the human. J Clin Invest 1957;36:1521-36.
14. Layer P, Go VL, DiMagno EP. Fate of pancreatic enzymes during small intestinal aboral transit in humans. Am J Physiol 1986;251:G475-80.
15. Granger M, Abadie B, Marchis-Mouren G. Limited action of trypsin on porcine pancreatic amylase: characterization of the fragments. FEBS Lett 1975;56:189-93.
16. Layer P, Jansen JB, Cherian L, Lamers CB, Goebell H. Feedback regulation of human pancreatic secretion: effects of protease inhibition on duodenal delivery and small intestinal transit of pancreatic enzymes. Gastroenterology 1990;98:1311-19.
17. Whitcomb DC. Acute pancreatitis. N Engl J Med 2006;354: 2142-50.
18. Robert JH, Frossard JL, Mermillod B, et al. Early prediction of acute pancreatitis: prospective study comparing computed tomography scans, Ranson, Glascow, acute physiology and chronic health evaluation II scores, and various serum markers. World J Surg 2002;26:612-19.
19. Jacobson BC, Baron TH, Adler DG, et al. ASGE guideline: the role of endoscopy in the diagnosis and the management of cystic lesions and inflammatory fluid collections of the pancreas. Gastrointest Endosc 2005;61:363-70.
20. Kozarek RA. Endoscopic therapy of complete and partial pancreatic duct disruptions. Gastrointest Endosc Clin N Am 1998;8:39-53.
21. Bradley EL III. A clinically based classification system for acute pancreatitis: summary of the international symposium on acute pancreatitis, Atlanta, GA, September 11-13, 1992. Arch Surg 1993;128:586-90.
22. Lankisch PG, Lembcke B, Wemken G, Creutzfeldt W. Functional reserve capacity of the exocrine pancreas. Digestion 1986;35:175-81.
23. Layer P, Yamamoto H, Kalthoff L, Clain JE, Bakken LJ, DiMagno EP. The different courses of early- and late-onset idiopathic and alcoholic chronic pancreatitis. Gastroenterology 1994;107:1481-7.
24. Baker SS, Borowitz D, Baker RD. Pancreatic exocrine function in patients with cystic fibrosis. Curr Gastroenterol Rep 2005;7:227-33.
25. 3-transport in mutations associated with cystic fibrosis. Nature 2001;410:94-7.
26. + channel (ENaC) requires CFTR Cl- channel function. Nature 1999;402:301-4.
27. Tucker JA, Spock A, Spicer SS, Shelburne JD, Bradford W. Inspissation of pancreatic zymogen material in cystic fibrosis. Ultrastruct Pathol 2003;27:323-35.
28. Jeffrey I, Durrans D, Wells M, Fox H. The pathology of meconium ileus equivalent. J Clin Pathol 1983;36:1292-7.
29. Forstner J, Wesley A, Mantle M, Kopelman H, Man D, Forstner G. Abnormal mucus: nominated but not yet elected. J Pediatr Gastroenterol Nutr 1984;3(suppl 1):S67-73.
30. Balasubramaniam KBC, Fin D, Batten JC, Northfield TC. Compensatory increase in lingual lipase activity and intragastric lipolysis in pancreatic steatorrhea caused by cystic fibrosis [abstract]. Gut 1985;26:576.
31. Guy-Crotte O, Carrere J, Figarella C. Exocrine pancreatic function in cystic fibrosis. Eur J Gastroenterol Hepatol 1996;8:755-9.
32. Layer P, von der Ohe MR, Holst JJ, et al. Altered postprandial motility in chronic pancreatitis: role of malabsorption. Gastroenterology 1997;112:1624-34.
33. Slaff J, Jacobson D, Tillman CR, Curington C, Toskes P. Protease-specific suppression of pancreatic exocrine secretion. Gastroenterology 1984;87:44-52.
34. Go VLW. The exocrine pancreas:' biology, pathobiology, and diseases, 2nd ed New York: Raven Press; 1993.
35. Bond JH, Currier BE, Buchwald H, Levitt MD. Colonic conservation of malabsorbed carbohydrate. Gastroenterology 1980;78:444-7.
36. Stephen AM, Haddad AC, Phillips SF. Passage of carbohydrate into the colon: direct measurements in humans. Gastroenterology 1983;85:589-95.
37. Read NW, McFarlane A, Kinsman RI, et al. Effect of infusion of nutrient solutions into the ileum on gastrointestinal transit and plasma levels of neurotensin and enteroglucagon. Gastroenterology 1984;86:274-80.
38. DiMagno EP, Malagelada JR, Go VL, Moertel CG. Fate of orally ingested enzymes in pancreatic insufficiency: comparison of two dosage schedules. N Engl J Med 1977;296:1318-22.
39. Holtmann G, Kelly DG, Sternby B, DiMagno EP. Survival of human pancreatic enzymes during small-bowel transit: effect of nutrients, bile acids, and enzymes. Am J Physiol 1997;273: G553-8.
40. Sternby BHG, Kelly DG, DiMagno EP. Effect of gastric or duodenal nutrient infusion on gastric and pancreatic lipase secretion [abstract]. Gastroenterology 1992;102:A292.
41. United States Pharmacopeial Convention. Pancreatin. Pancrelipase. In: The United States pharmacopeia, 30th ed. The national formulary, 25th ed. Rockville, MD: United States Pharmacopeial Convention, Inc.; 2007:2850-4.
42. Stapleton FB, Kennedy J, Nousia-Arvanitakis S, Linshaw MA. Hyperuricosuria due to high-dose pancreatic extract therapy in cystic fibrosis. N Engl J Med 1976;295:246-8.
43. Graham DY. Enzyme replacement therapy of exocrine pancreatic insufficiency in man: relations between in vitro enzyme activities and in vivo potency in commercial pancreatic extracts. N Engl J Med 1977;296:1314-17.
44. Durie PR, Bell L, Linton W, Corey ML, Forstner GG. Effect of cimetidine and sodium bicarbonate on pancreatic replacement therapy in cystic fibrosis. Gut 1980;21:778-86.
45. Francisco MP, Wagner MH, Sherman JM, Theriaque D, Bowser E, Novak DA. Ranitidine and omeprazole as adjuvant therapy to pancrelipase to improve fat absorption in patients with cystic fibrosis. J Pediatr Gastroenterol Nutr 2002;35: 79-83.
46. Hendeles L, Dorf A, Stecenko A, Weinberger M. Treatment failure after substitution of generic pancrelipase capsules: correlation with in vitro lipase activity. JAMA 1990;263: 2459-61.
47. Brady MS, Garson JL, Krug SK, et al. An enteric-coated high-buffered pancrelipase reduces steatorrhea in patients with cystic fibrosis: a prospective, randomized study. J Am Diet Assoc 2006;106:1181-6.
48. Kalnins D, Ellis L, Corey M, et al. Enteric-coated pancreatic enzyme with bicarbonate is equal to standard enteric-coated enzyme in treating malabsorption in cystic fibrosis. J Pediatr Gastroenterol Nutr 2006;42:256-61.
49. Butt AM, Ip W, Ellis L, et al. The fate of ingested enzymes in cystic fibrosis [abstract]. Pediatr Pulm 2001;32(S22):137-8.
50. U.S. Food and Drug Administration, Center for Drug Evaluation and Research. Questions and answers on exocrine pancreatic insufficiency drug products. Available from http://www.fda.gov/cder/drug/infopage/pancreatic_drugs/ pancreatic_QA.htm. Accessed November 20, 2006.
51. Stevens JC, Davis M, Pawel BR, et al. Fibrosing colonopathy (FC): retrospective analysis of U.S. cases 1995-1999 [abstract]. Pediatr Pulm 2001;32(S22):501.
52. Regan PT, Malagelada JR, DiMagno EP, Glanzman SL, Go VL. Comparative effects of antacids, cimetidine and enteric coating on the therapeutic response to oral enzymes in severe pancreatic insufficiency. N Engl J Med 1977;297:854-8.
53. Layer P, von der Ohe M, Groger G, Dicke D, Goebell H. Luminal availability and digestive efficacy of substituted enzymes in pancreatic insufficiency [abstract]. Pancreas 1992;7:745.
54. FitzSimmons SC, Burkhart GA, Borowitz D, et al. High-dose pancreatic-enzyme supplements and fibrosing colonopathy in children with cystic fibrosis. N Engl J Med 1997;336:1283-9.
55. Layer P, Keller J, Lankisch PG. Pancreatic enzyme replacement therapy. Curr Gastroenterol Rep 2001;3:101-8.
56. Lankisch PG. Pancreatic enzyme therapy following surgical procedures in the gastrointestinal tract. Pancreatology 2001;1(suppl 1):1-72.
57. Lankisch PG. Appropriate pancreatic function tests and indication for pancreatic enzyme therapy following surgical procedures on the pancreas. Pancreatology 2001;1(suppl 1):14-26.
58. Owyang C. Negative feedback control of exocrine pancreatic secretion: role of cholecystokinin and cholinergic pathway. J Nutr 1994;124(suppl 8):S1321-6.
59. Isaksson G, Ihse I. Pain reduction by an oral pancreatic enzyme preparation in chronic pancreatitis. Dig Dis Sci 1983;28:97-102.
60. Mossner J. Palliation of pain in chronic pancreatitis: use of enzymes. Surg Clin North Am 1999;79:861-72.
61. Halgreen H, Pedersen NT, Worning H. Symptomatic-effect of pancreatic enzyme therapy in patients with chronic pancreatitis. Scand J Gastroenterol 1986;21:104-8.
62. Malesci A, Gaia E, Fioretta A, et al. No effect of long-term treatment with pancreatic extract on recurrent abdominal pain in patients with chronic pancreatitis. Scand J Gastroenterol 1995;30:392-8.
63. Malfertheiner P, Mayer D, Buchler M, Dominguez-Munoz JE, Schiefer B, Ditschuneit H. Treatment of pain in chronic pancreatitis by inhibition of pancreatic secretion with octreotide. Gut 1995;36:450-4.
64. Leung JW, Bowen-Wright M, Aveling W, Shorvon PJ, Cotton PB. Coeliac plexus block for pain in pancreatic cancer and chronic pancreatitis. Br J Surg 1983;70:730-2.
65. Bakowski MPP. Epidemiology of fibrosing colonopathy: US versus UK 1991-2001 [abstract]. J Cyst Fibros 2002;1(suppl 1):abstract P288.
66. Schibli S, Durie PR, Tullis ED. Proper usage of pancreatic enzymes. Curr Opin Pulm Med 2002;8:542-6.
67. Raimondo M, DiMagno EP. Lipolytic activity of bacterial lipase survives better than that of porcine lipase in human gastric and duodenal content. Gastroenterology 1994;107:231-5.
68. Suzuki A, Mizumoto A, Rerknimitr R, Sarr MG, DiMagno EP. Effect of bacterial or porcine lipase with low- or high-fat diets on nutrient absorption in pancreatic-insufficient dogs. Gastroenterology 1999;116:431-7.
69. Borowitz D, Goss CH, Stevens C, et al. Safety and preliminary clinical activity of a novel pancreatic enzyme preparation in pancreatic insufficient cystic fibrosis patients. Pancreas 2006;32:258-63.